Kedrion Biopharma attends ASHP 2016 midyear clinical meeting

Kedrion Biopharma participated in the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting at the Mandalay Bay Convention Center in Las Vegas, Nevada. From December 4-8, more than 20,000 pharmacy professionals around the globe met with a focus on improving patient care and medication safety. Having attended the ASHP Midyear Meeting for the past five years, Kedrion Biopharma has recognized the changing role of pharmacists in the decision-making process. To keep abreast of their changing roles, representatives from the Senior Commercial team attended ASHP this year.

This year’s meeting provided an opportunity for Kedrion Biopharma to gain important insights on hyperimmunes. Kedrion Biopharma coordinated efforts with ASHP to schedule targeted focus groups. Neal C. Fitzpatrick, VP Commercial Head, North America, explained, “We held a focus group with this key audience, which helped us ascertain important insights from pharmacists as it relates to the use of anti-D products.”

In addition, Kedrion Biopharma had a chance to meet with customers one-on-one at ASHP. According to Jerry Sosin, Sr. Director, National Accounts and Managed Markets, “Our team of National Account Managers had the chance to have in-depth, one-on-one meetings with existing and potential new customers to discuss Kedrion and its portfolio of products.”

Founded over 75 years ago, the ASHP represents over 40,000 pharmacists, pharmacy students, and pharmacy technicians who serve as patient care providers on healthcare teams in acute and ambulatory care settings. Kedrion Biopharma’s presence at these meetings allows the company to demonstrate its continued commitment and dedication to the pharmacy community serving plasma protein patients.


About Kedrion Biopharma

Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization. Kedrion Biopharma Inc., the US subsidiary of Kedrion Biopharma, is headquartered in Fort Lee, New Jersey. Kedrion Biopharma launched US operations in 2011, but the company’s international roots stretch back several decades in the production of blood and plasma-derived products. Kedrion Biopharma places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Additional information about Kedrion Biopharma can be found at and

©2016 Kedrion Biopharma Inc. All Rights Reserved. December 2016 CO-0435-00-2016